Delivery Order SPE2DB22D3011-SPE2DB25FQ2KV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $30,166.02 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Pulmozyme is a prescribed medication used primarily in the treatment of cystic fibrosis,...
- The Defense Logistics Agency awarded a delivery order valued at $6,018.36 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units) on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract employs firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,594.39 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract requires performance at AmerisourceBergen's Conshohocken, Pennsylvania location. Pulmozyme is a recombinant human deoxyribonuclease used primarily in the treatment of cystic fibrosis, reflecting the Defense Logistics Agency's ongoing...
- The Defense Logistics Agency awarded a $9.68K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on July 23, 2025, with completion expected by July 24, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99M vehicle extending through...
- The Defense Logistics Agency awarded a $5,167.20 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml units) under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a purchase order for a respiratory medication commonly used in the treatment of cystic fibrosis and is being delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. The contract was awarded on...
- The Defense Logistics Agency (DLA) awarded a $48,488.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units). The contract, which was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL pharmaceutical product. This is a firm fixed price delivery order with a ceiling value of $2,583.60 and an ultimate completion date of July 28, 2025. The contract was awarded without a set-aside designation through competitive procurement, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,721.78 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL units). The contract employs firm fixed price terms with no set-aside designation, indicating competitive award based on open competition. Performance is scheduled to conclude by August 18, 2025, with fulfillment occurring at the contractor's Conshohocken, Pennsylvania facility. This delivery order represents a child...
- The Defense Logistics Agency awarded a $2,583.60 delivery order to AmerisourceBergen Drug Corp for PULMOZYME 1 mg/ml ampules (2.5 ml units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with the Defense...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL pharmaceutical product, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2KVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on August 25, 2025, with a ceiling value of $24,334.03 and ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply delivery under the company's existing contract vehicle with the federal government's medical procurement system. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs globally. Pulmozyme, a medication used primarily for cystic fibrosis treatment, represents the type of specialized pharmaceutical commodity the vendor routinely delivers to support Defense Health Agency and other federal healthcare system requirements. As a major pharmaceutical distributor and critical vendor in the federal medical supply chain, AmerisourceBergen Drug Corp maintains a substantial portfolio of competitively awarded contracts with the Defense Logistics Agency for diverse therapeutic categories spanning specialty medications, vaccines, and medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.3k | 8/25/25 |